Holen Sie sich die Stockscreener-App
9.49
0.32%
-0.03
Handel nachbörslich:
9.49
Schlusskurs vom Vortag:
$9.52
Offen:
$9.55
24-Stunden-Volumen:
176.89K
Relative Volume:
0.96
Marktkapitalisierung:
$473.32M
Einnahmen:
$62.02M
Nettoeinkommen (Verlust:
$-45.65M
KGV:
0.8354
EPS:
11.36
Netto-Cashflow:
$-9.60M
1W Leistung:
+4.52%
1M Leistung:
+7.84%
6M Leistung:
+2.15%
1J Leistung:
-9.19%
1-Tages-Spanne:
$9.425
$9.675
1-Wochen-Bereich:
$8.84
$10.26
52-Wochen-Spanne:
$7.44
$11.71
Theravance Biopharma Inc Stock (TBPH) Company Profile
Firmenname
Theravance Biopharma Inc
Sektor
Branche
Telefon
650-808-6000
Adresse
UGLAND HOUSE, SOUTH CHURCH STREET, GEORGE TOWN, GRAND CAYMAN
Vergleichen Sie TBPH mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| TBPH | 9.49 | 473.32M | 62.02M | -45.65M | -9.60M | 11.36 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Theravance Biopharma Inc Stock (TBPH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
| 2021-11-05 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2021-09-15 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2021-08-25 | Herabstufung | Morgan Stanley | Overweight → Underweight |
| 2021-08-24 | Herabstufung | Cowen | Outperform → Market Perform |
| 2020-10-14 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-07-07 | Eingeleitet | JP Morgan | Overweight |
| 2020-06-15 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2020-05-13 | Eingeleitet | Cowen | Outperform |
| 2020-01-08 | Bestätigt | H.C. Wainwright | Buy |
| 2019-11-06 | Hochstufung | Robert W. Baird | Underperform → Neutral |
| 2019-10-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-03-29 | Fortgesetzt | Piper Jaffray | Overweight |
| 2017-08-17 | Eingeleitet | Evercore ISI | Outperform |
| 2017-06-16 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2017-05-11 | Bestätigt | Needham | Buy |
| 2016-12-21 | Eingeleitet | Needham | Buy |
| 2016-11-03 | Eingeleitet | Piper Jaffray | Overweight |
| 2016-10-12 | Herabstufung | Robert W. Baird | Neutral → Underperform |
| 2016-08-03 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2016-06-20 | Eingeleitet | Guggenheim | Buy |
| 2016-06-20 | Bestätigt | Leerink Partners | Outperform |
| 2016-05-12 | Eingeleitet | Leerink Partners | Outperform |
| 2016-05-05 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2015-02-03 | Hochstufung | Robert W. Baird | Underperform → Neutral |
Alle ansehen
Theravance Biopharma Inc Aktie (TBPH) Neueste Nachrichten
(TBPH) Investment Report - Stock Traders Daily
Theravance Biopharma Inc (TBPH) Quarterly 10-Q Report - Quartzy
Madison Avenue Partners, LP Expands Stake in Theravance Biopharm - GuruFocus.com
Theravance Biopharma Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Analysts Set Theravance Biopharma, Inc. (NASDAQ:TBPH) PT at $13.75 - MarketBeat
Theravance Biopharma SVP Rhonda Farnum sells $36,000 in shares - Investing.com India
Theravance Biopharma SVP Rhonda Farnum sells $36,000 in shares By Investing.com - Investing.com Canada
Theravance's Q3 Loss Narrower Than Expected, Revenues Rise Y/Y - Yahoo Finance
Theravance Biopharma, Inc. (NASDAQ:TBPH) Q3 2024 Earnings Call Transcript - Insider Monkey
Theravance Biopharma (NASDAQ:TBPH) Stock Price Crosses Above Fifty Day Moving AverageTime to Sell? - MarketBeat
Theravance Biopharma Inc (TBPH) Q3 2024 Earnings Call Highlights: Strong Sales Growth and Strategic Initiatives - GuruFocus.com
Theravance Biopharma Inc (TBPH) Q3 2024 Earnings Call Highlights: Strong Sales Growth and ... - Yahoo Finance
Theravance Biopharma’s Third Quarter 2024 Financial Insights - TipRanks
Theravance Biopharma (TBPH) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Theravance Biopharma Q3 2024 Earnings: Revenue Surpasses Estimat - GuruFocus.com
Theravance Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
With Theravance Biopharma, Inc. (NASDAQ:TBPH) It Looks Like You'll Get What You Pay For - Simply Wall St
What To Expect From Theravance Biopharma Inc (TBPH) Q3 2024 Earnings - GuruFocus.com
Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar and Theravance - Yahoo Finance
Theravance Biopharma (TBPH) Scheduled to Post Earnings on Tuesday - Defense World
5 Small Drug Stocks to Buy as Trump Gets Re-Elected - Yahoo Finance
Theravance Biopharma (TBPH) Set to Announce Quarterly Earnings on Tuesday - MarketBeat
Vanguard Group Inc's Strategic Acquisition in Theravance Biophar - GuruFocus.com
(TBPH) Proactive Strategies - Stock Traders Daily
Theravance Biopharma, Inc. (NASDAQ:TBPH) Shares Sold by SG Americas Securities LLC - MarketBeat
When (TBPH) Moves Investors should Listen - Stock Traders Daily
Theravance Biopharma to Report Third Quarter 2024 Financial Results on November 12, 2024 - StockTitan
Q3 EPS Estimate for Theravance Biopharma Boosted by Analyst - MarketBeat
Brokerages Set Theravance Biopharma, Inc. (NASDAQ:TBPH) PT at $13.75 - Defense World
What is Zacks Research's Estimate for TBPH Q4 Earnings? - MarketBeat
Theravance Biopharma, Inc. (NASDAQ:TBPH) Given Average Rating of "Hold" by Analysts - MarketBeat
The Manufacturers Life Insurance Company Decreases Stake in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Theravance study shows YUPELRI improves COPD lung function By Investing.com - Investing.com Australia
Theravance Biopharma (NASDAQ:TBPH) Shares Pass Below 200 Day Moving AverageHere's What Happened - MarketBeat
Theravance study shows YUPELRI improves COPD lung function - Investing.com
Theravance Announces Publication of YUPELRI® (revefenacin) Area Under the Curve Spirometry Analysis in the International Journal of Chronic Obstructive Pulmonary Disease - StockTitan
Where are the Opportunities in (TBPH) - Stock Traders Daily
Dimensional Fund Advisors LP Has $2.80 Million Stake in Theravance Biopharma, Inc. (NASDAQ:TBPH) - MarketBeat
Theravance Biopharma (STU:0TB) Price-to-Operating-Cash-Flow : (As of Oct. 10, 2024) - GuruFocus.com
Squarepoint Ops LLC Takes $986,000 Position in Theravance Biopharma, Inc. (NASDAQ:TBPH) - MarketBeat
Bank of Montreal Can Raises Stock Position in Theravance Biopharma, Inc. (NASDAQ:TBPH) - MarketBeat
Theravance Biopharma, Inc. (NASDAQ:TBPH) Stock Holdings Lifted by Marshall Wace LLP - MarketBeat
(TBPH) Pivots Trading Plans and Risk Controls - Stock Traders Daily
XTX Topco Ltd Purchases New Holdings in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Theravance (TBPH) Q2 Loss Wider Than Expected, Revenues Rise Y/Y - MSN
Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives Consensus Recommendation of “Hold” from Brokerages - Defense World
Rhumbline Advisers Sells 15,095 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
An Analysis of Theravance Biopharma Inc (TBPH)’s Potential Price Growth - Knox Daily
Theravance Biopharma settles patent litigation with Qilu Pharmaceutical - Investing.com
Baupost Group LLC MA Decreases Holdings in Theravance Biopharma, Inc. (NASDAQ:TBPH) - MarketBeat
Finanzdaten der Theravance Biopharma Inc-Aktie (TBPH)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):